Home › Burkitt Lymphoma › NCT07117136
Blinatumomab Consolidation in Real World
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2022 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients Exclusion Criteria: * N/A
About the study
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Sponsor: Medical College of Wisconsin · Participants: 200 · Started: Aug 28, 2025
Contact the study team
- Arielle Baim · Phone: 4148058745
Official record on ClinicalTrials.gov — NCT07117136
Locations in the U.S.
| Florida | Mayo Clinic Cancer Center, Jacksonville |
| Pennsylvania | University of Pennsylvania, Philadelphia |
| Wisconsin | Medical College of Wisconsin, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.